1 reports of this reaction
50.0% of all BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE reports
#1 most reported adverse reaction
DISEASE PROGRESSION is the #1 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 1 FDA adverse event reports linking BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE to DISEASE PROGRESSION. This represents approximately 50.0% of all 2 adverse event reports for this drug.
Patients taking BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is a frequently reported adverse event for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to disease progression, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 1 FDA reports for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 50.0% of all adverse event reports for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience disease progression while taking BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.